DERMATA THERAPEUTICS INC DRMAW 深 滬
已收盤 02-06 16:00:00 美东时间
0.0194
0.000
-0.51%
華盛通- 最 高0.0195
- 今 開0.0194
- 成交量 8462股
- 最 低 0.0169
- 昨 收 0.0195
- 總市值 0
- 52周最高 0.044
- 市盈率 靜 --
- 換手率 Infinity.00%
- 52周最低 0.0102
- 委 比 12.40%
- 總股本 --
- 歷史最高 1.70
- 量 比 1.31
- 振 幅 13.33%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dermata Therapeutics Announces Private Placement Up To $12.4M
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and
2025-12-24 21:01
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
2025-10-02 20:02
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
2025-09-10 20:09
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product ...
2025-03-27 20:00
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (...
2024-03-22 04:05
Dermata Enrolls First Patient In Pivotal DMT310 Phase 3 STAR-1 Clinical Trial For Acne; About 550 Patients Will Be Treated Once Weekly For 12 Weeks
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20,
2023-12-21 05:09
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasd...
2023-08-31 09:00
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Derm...
2023-03-21 04:31
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Der...
2021-08-18 09:21
